新型泛ERR激动剂通过增强心肌脂肪酸代谢和线粒体功能改善心力衰竭
该研究基于结构设计合成两种泛ERR激动剂SLU-PP-332和SLU-PP-915,在压力超负荷诱导的心衰模型中验证其疗效。两种化合物显著改善射血分数、减轻纤维化并提高生存率,且不改变心肌肥厚;多组学和遗传依赖实验表明ERRγ介导转录调控和心脏保护,靶点特异性明确。
要点
- 泛ERR激动剂改善压力超负荷心衰小鼠的射血分数、纤维化及生存率
- ERR激动剂激活脂肪酸代谢和线粒体功能相关基因,恢复代谢谱
- ERRγ是ERR激动剂诱导转录调控和心脏保护的主要介导者
核心结论
- ERR激动剂维持氧化代谢,在体内对压力超负荷诱导的心衰提供心脏保护。
- 结果为ERR激动剂作为新型心衰治疗药物进一步开发提供直接药理学证据。
研究设计与样本
- 采用基于结构的药物设计方法,设计并合成2种结构不同的泛ERR激动剂SLU-PP-332和SLU-PP-915。
- 在体内压力超负荷诱导的心衰模型中研究ERR激动剂对心脏功能的影响。
- 在体内和体外进行综合功能、多组学(RNA测序和代谢组学)及遗传依赖研究。
主要发现
- SLU-PP-332和SLU-PP-915均显著改善射血分数、减轻纤维化并提高生存率,且不改变心肌肥厚。
- ERR激动剂转录激活广谱代谢基因,尤其是脂肪酸代谢和线粒体功能相关基因。
- 代谢组学分析显示6周压力超负荷小鼠心脏中脂肪酸/脂质和三羧酸/氧化磷酸化代谢物谱显著正常化。
- ERR激动剂在体外和体内增加线粒体氧化能力和脂肪酸利用。
- ERRγ是ERR激动剂诱导转录调控和心脏保护的主要介导者,并明确证明了靶点特异性。
临床怎么用
- ERR激动剂可能作为改善心衰代谢功能障碍的新型治疗策略,但尚需临床研究验证。
局限性
- 研究仅基于压力超负荷诱导的临床前心衰模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism. Therefore, activation of ERR could be a potential therapeutic intervention for HF. However, in vivo studies demonstrating the potential usefulness of ERR agonist for HF treatment are lacking, because compounds with pharmacokinetics appropriate for in vivo use have not been available. METHODS: Using a structure-based design approach, we designed and synthesized 2 structurally distinct pan-ERR agonists, SLU-PP-332 and SLU-PP-915. We investigated the effect of ERR agonist on cardiac function in a pressure overload-induced HF model in vivo. We conducted comprehensive functional, multi-omics (RNA sequencing and metabolomics studies), and genetic dependency studies both in vivo and in vitro to dissect the molecular mechanism, ERR isoform dependency, and target specificity. RESULTS: Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival associated with pressure overload-induced HF without affecting cardiac hypertrophy. A broad spectrum of metabolic genes was transcriptionally activated by ERR agonists, particularly genes involved in fatty acid metabolism and mitochondrial function. Metabolomics analysis showed substantial normalization of metabolic profiles in fatty acid/lipid and tricarboxylic acid/oxidative phosphorylation metabolites in the mouse heart with 6-week pressure overload. ERR agonists increase mitochondria oxidative capacity and fatty acid use in vitro and in vivo. Using both in vitro and in vivo genetic dependency experiments, we show that ERRγ is the main mediator of ERR agonism-induced transcriptional regulation and cardioprotection and definitively demonstrated target specificity. ERR agonism also led to downregulation of cell cycle and development pathways, which was partially mediated by E2F1 in cardiomyocytes. CONCLUSIONS: ERR agonists maintain oxidative metabolism, which confers cardiac protection against pressure overload-induced HF in vivo. Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics.
引用
- Xu, Billon, Li, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2023. PMID: 37961903. doi:10.1161/CIRCULATIONAHA.123.066542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。